BIOVAXYS

BioVaxys Technology Corp, a leader in biopharmaceutical innovation focused on antiviral and cancer vaccine development. Leveraging our recent acquisition of IMV INC's IP, we're at the forefront of advancing DPX™ delivery technology and haptenized protein vaccines, targeting solid tumors and various viral infections... We are exploring the use of Artificial Intelligence to enhance immunotherapeutic discovery. Our goal is to develop proprietary algorithms, enhancing our understanding of antigen structures and T-cell responses... We collaborate with leading institutions and universities and hold exclusive patents in haptenized vaccine technologies and T cell-mediated immune response diagnostics.

Also known as: BioVaxys Technology Corp., BioVaxys Technology Corporation

Primary location: New York United States